Clinical trials: Malignant Pelvic Neoplasm

Carcinoma, Renal Cell

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

• Terminated
• Age: 18 years and older
• Phase 1
• Surgery or procedure

Patients with rectal cancer who are candidates for pre-operative radiation therapy may be enrolled in the Phase I, single center study.

Trial name

NCT00158886

Testing

Topotecan, Radiation therapy

Where

United States

Volunteers

26 people

Sponsor

GlaxoSmithKline